KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Enterprise Value (2016 - 2025)

Vertex Pharmaceuticals has reported Enterprise Value over the past 17 years, most recently at -$6.6 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$6.6 billion for Q4 2025, down 8.05% from a year ago — trailing twelve months through Dec 2025 was -$6.6 billion (down 8.05% YoY), and the annual figure for FY2025 was -$6.6 billion, down 8.05%.
  • Enterprise Value for Q4 2025 was -$6.6 billion at Vertex Pharmaceuticals, down from -$6.3 billion in the prior quarter.
  • Over the last five years, Enterprise Value for VRTX hit a ceiling of -$5.8 billion in Q2 2024 and a floor of -$11.9 billion in Q3 2023.
  • Median Enterprise Value over the past 5 years was -$7.2 billion (2021), compared with a mean of -$8.3 billion.
  • Biggest five-year swings in Enterprise Value: plummeted 65.23% in 2021 and later skyrocketed 48.42% in 2024.
  • Vertex Pharmaceuticals' Enterprise Value stood at -$7.5 billion in 2021, then crashed by 43.24% to -$10.8 billion in 2022, then dropped by 4.08% to -$11.2 billion in 2023, then skyrocketed by 45.48% to -$6.1 billion in 2024, then decreased by 8.05% to -$6.6 billion in 2025.
  • The last three reported values for Enterprise Value were -$6.6 billion (Q4 2025), -$6.3 billion (Q3 2025), and -$6.4 billion (Q2 2025) per Business Quant data.